tDCS + Cognitive Training for Post-Stroke Cognitive Impairment
(TIPSCI Trial)
Trial Summary
What is the purpose of this trial?
The investigators will conduct a randomized, double-blinded, sham-controlled trial of approximately 60 patients with minor stroke and post-stroke mild cognitive impairment (psMCI). Participants will be individually randomized on enrollment using a random number generator to treatment with anodal tDCS + computerized cognitive treatment (CCT) versus sham + CCT (approximately 30 patients in each arm). Clinical evaluation including assessment of cognition will be performed pre- and post-intervention by individuals on the study team blinded to the participant's intervention. Participants will also undergo functional neuroimaging with magnetoencephalography (MEG) pre- and post-intervention (1, 3, and 6 months post-stroke to evaluate for initial and longer-term effects of treatment on cerebral activation patterns and functional connectivity). Neuroimaging and clinical outcomes will be assessed to determine the effect of tDCS versus sham + CCT on psMCI.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the treatment Anodal transcranial Direct Current Stimulation (A-tDCS) combined with cognitive training effective for improving cognitive function in post-stroke patients?
Research shows that combining transcranial direct current stimulation (tDCS) with cognitive training can improve cognitive performance during the stimulation in healthy individuals, but the benefits do not necessarily lead to long-term learning improvements. In stroke patients, while cognitive training alone showed significant improvements, adding tDCS did not provide additional benefits.12345
Is transcranial direct current stimulation (tDCS) safe for humans?
Transcranial direct current stimulation (tDCS) is generally considered safe for humans, with studies showing no serious adverse effects in over 33,200 sessions across various populations, including potentially vulnerable groups. However, some reports suggest it could potentially cause significant conditions in healthy individuals, so caution is advised.46789
How does the treatment Anodal tDCS differ from other treatments for post-stroke cognitive impairment?
Anodal tDCS is a non-invasive brain stimulation technique that uses a mild electrical current to enhance cognitive function, which is different from traditional drug-based treatments. It is often combined with cognitive training to potentially improve cognitive performance, although its effects can be less predictable and vary among individuals.35101112
Research Team
Elisabeth B Marsh, MD
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for adults over 18 who've had a minor stroke within the last week and show mild cognitive issues afterward. They must speak English, have manageable stroke symptoms (NIHSS <8), and be relatively independent (mRS 0-2). People with dementia, severe psychiatric illness, or those unable to attend sessions are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 15 sessions of anodal tDCS or sham intervention over 5 weeks, combined with computerized cognitive therapy (CCT)
Follow-up
Participants are monitored for safety and effectiveness after treatment, with MEG and cognitive assessments at 1, 3, and 6 months post-stroke
Treatment Details
Interventions
- Anodal transcranial Direct Current Stimulation (A-tDCS)
- Sham Intervention
Anodal transcranial Direct Current Stimulation (A-tDCS) is already approved in United States, European Union, China for the following indications:
- Post-stroke cognitive impairment
- Post-stroke depression
- Aphasia
- Central post-stroke pain
- Post-stroke cognitive impairment
- Post-stroke depression
- Aphasia
- Central post-stroke pain
- Post-stroke cognitive impairment
- Post-stroke depression
- Aphasia
- Central post-stroke pain
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
University of Maryland, College Park
Collaborator